Success is hard to come by in drug development. “On average, 50% of phase III trials with novel therapeutics fail,” says Subha Madhavan, vice president and head of AI/ML at Pfizer. “A primary reason ...
Every research lab is constantly innovating; either by creating something new or by understanding the equations and statistics underlying each vital subject, the stakes are high. With trillions of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback